Diagnosis and management of urothelial carcinoma in situ of the lower urinary tract: A systematic review

Rowan G. Casey, James W F Catto, Liang Cheng, Michael S. Cookson, Harry Herr, Sharokh Shariat, J. Alfred Witjes, Peter C. Black

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Context Urothelial carcinoma in situ (CIS) has a high propensity for progression. It is usually reported within the heterogeneous context of non-muscle-invasive bladder cancer (NMIBC) but warrants special consideration. Objective To review the contemporary literature on the diagnosis and management of CIS. Evidence acquisition A systematic search using broad terms to capture the diagnosis and treatment of CIS was performed according to Preferred Reporting Items for Systematic Reviews and Meta-analysis criteria. Full-text original articles, reviews, and editorials from 1966 to 2014 in English were included. References from selected articles, relevant guidelines, and conference abstracts were searched. Abstracts were excluded. Evidence synthesis A total of 1887 articles were identified, of which 120 were used in this review. Most reports were retrospective and heterogeneous in caseload. There is a lack of standardised classification of CIS. Many studies consider CIS in the context of NMIBC without a clear separation of the subset with CIS. Recent prospective phase 2 and 3 studies have improved the evidence base. Conclusions We are beginning to understand that CIS has a spectrum of biologic potential. Bacillus Calmette-Guérin immunotherapy appears superior to other intravesical agents and may alter the natural history of CIS. New imaging modalities, agents, and treatment strategies have emerged in recent years with the aim of better identification of CIS, more bladder-preserving treatments, and prevention of surgical overtreatment. Patient summary Improvements in imaging techniques combined with new bladder-preserving treatments will continue to have an impact on the outcomes of bladder carcinoma in situ.

Original languageEnglish (US)
Pages (from-to)876-888
Number of pages13
JournalEuropean Urology
Volume67
Issue number5
DOIs
StatePublished - May 1 2015

Fingerprint

Carcinoma in Situ
Urinary Tract
Urinary Bladder
Urinary Bladder Neoplasms
Therapeutics
Immunotherapy
Bacillus
Meta-Analysis
Guidelines

Keywords

  • Bacillus Calmette-Guérin
  • Bladder
  • Fluorescent cystoscopy
  • Gemcitabine
  • Hyperthermia
  • Interferon-α
  • Intravesical immunotherapy
  • Narrow-band cystoscopy
  • Photodynamic diagnosis
  • Urothelial carcinoma in situ
  • Valrubicin

ASJC Scopus subject areas

  • Urology

Cite this

Diagnosis and management of urothelial carcinoma in situ of the lower urinary tract : A systematic review. / Casey, Rowan G.; Catto, James W F; Cheng, Liang; Cookson, Michael S.; Herr, Harry; Shariat, Sharokh; Witjes, J. Alfred; Black, Peter C.

In: European Urology, Vol. 67, No. 5, 01.05.2015, p. 876-888.

Research output: Contribution to journalArticle

Casey, RG, Catto, JWF, Cheng, L, Cookson, MS, Herr, H, Shariat, S, Witjes, JA & Black, PC 2015, 'Diagnosis and management of urothelial carcinoma in situ of the lower urinary tract: A systematic review', European Urology, vol. 67, no. 5, pp. 876-888. https://doi.org/10.1016/j.eururo.2014.10.040
Casey, Rowan G. ; Catto, James W F ; Cheng, Liang ; Cookson, Michael S. ; Herr, Harry ; Shariat, Sharokh ; Witjes, J. Alfred ; Black, Peter C. / Diagnosis and management of urothelial carcinoma in situ of the lower urinary tract : A systematic review. In: European Urology. 2015 ; Vol. 67, No. 5. pp. 876-888.
@article{f05d306d62d044d7989ff96873635df3,
title = "Diagnosis and management of urothelial carcinoma in situ of the lower urinary tract: A systematic review",
abstract = "Context Urothelial carcinoma in situ (CIS) has a high propensity for progression. It is usually reported within the heterogeneous context of non-muscle-invasive bladder cancer (NMIBC) but warrants special consideration. Objective To review the contemporary literature on the diagnosis and management of CIS. Evidence acquisition A systematic search using broad terms to capture the diagnosis and treatment of CIS was performed according to Preferred Reporting Items for Systematic Reviews and Meta-analysis criteria. Full-text original articles, reviews, and editorials from 1966 to 2014 in English were included. References from selected articles, relevant guidelines, and conference abstracts were searched. Abstracts were excluded. Evidence synthesis A total of 1887 articles were identified, of which 120 were used in this review. Most reports were retrospective and heterogeneous in caseload. There is a lack of standardised classification of CIS. Many studies consider CIS in the context of NMIBC without a clear separation of the subset with CIS. Recent prospective phase 2 and 3 studies have improved the evidence base. Conclusions We are beginning to understand that CIS has a spectrum of biologic potential. Bacillus Calmette-Gu{\'e}rin immunotherapy appears superior to other intravesical agents and may alter the natural history of CIS. New imaging modalities, agents, and treatment strategies have emerged in recent years with the aim of better identification of CIS, more bladder-preserving treatments, and prevention of surgical overtreatment. Patient summary Improvements in imaging techniques combined with new bladder-preserving treatments will continue to have an impact on the outcomes of bladder carcinoma in situ.",
keywords = "Bacillus Calmette-Gu{\'e}rin, Bladder, Fluorescent cystoscopy, Gemcitabine, Hyperthermia, Interferon-α, Intravesical immunotherapy, Narrow-band cystoscopy, Photodynamic diagnosis, Urothelial carcinoma in situ, Valrubicin",
author = "Casey, {Rowan G.} and Catto, {James W F} and Liang Cheng and Cookson, {Michael S.} and Harry Herr and Sharokh Shariat and Witjes, {J. Alfred} and Black, {Peter C.}",
year = "2015",
month = "5",
day = "1",
doi = "10.1016/j.eururo.2014.10.040",
language = "English (US)",
volume = "67",
pages = "876--888",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier",
number = "5",

}

TY - JOUR

T1 - Diagnosis and management of urothelial carcinoma in situ of the lower urinary tract

T2 - A systematic review

AU - Casey, Rowan G.

AU - Catto, James W F

AU - Cheng, Liang

AU - Cookson, Michael S.

AU - Herr, Harry

AU - Shariat, Sharokh

AU - Witjes, J. Alfred

AU - Black, Peter C.

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Context Urothelial carcinoma in situ (CIS) has a high propensity for progression. It is usually reported within the heterogeneous context of non-muscle-invasive bladder cancer (NMIBC) but warrants special consideration. Objective To review the contemporary literature on the diagnosis and management of CIS. Evidence acquisition A systematic search using broad terms to capture the diagnosis and treatment of CIS was performed according to Preferred Reporting Items for Systematic Reviews and Meta-analysis criteria. Full-text original articles, reviews, and editorials from 1966 to 2014 in English were included. References from selected articles, relevant guidelines, and conference abstracts were searched. Abstracts were excluded. Evidence synthesis A total of 1887 articles were identified, of which 120 were used in this review. Most reports were retrospective and heterogeneous in caseload. There is a lack of standardised classification of CIS. Many studies consider CIS in the context of NMIBC without a clear separation of the subset with CIS. Recent prospective phase 2 and 3 studies have improved the evidence base. Conclusions We are beginning to understand that CIS has a spectrum of biologic potential. Bacillus Calmette-Guérin immunotherapy appears superior to other intravesical agents and may alter the natural history of CIS. New imaging modalities, agents, and treatment strategies have emerged in recent years with the aim of better identification of CIS, more bladder-preserving treatments, and prevention of surgical overtreatment. Patient summary Improvements in imaging techniques combined with new bladder-preserving treatments will continue to have an impact on the outcomes of bladder carcinoma in situ.

AB - Context Urothelial carcinoma in situ (CIS) has a high propensity for progression. It is usually reported within the heterogeneous context of non-muscle-invasive bladder cancer (NMIBC) but warrants special consideration. Objective To review the contemporary literature on the diagnosis and management of CIS. Evidence acquisition A systematic search using broad terms to capture the diagnosis and treatment of CIS was performed according to Preferred Reporting Items for Systematic Reviews and Meta-analysis criteria. Full-text original articles, reviews, and editorials from 1966 to 2014 in English were included. References from selected articles, relevant guidelines, and conference abstracts were searched. Abstracts were excluded. Evidence synthesis A total of 1887 articles were identified, of which 120 were used in this review. Most reports were retrospective and heterogeneous in caseload. There is a lack of standardised classification of CIS. Many studies consider CIS in the context of NMIBC without a clear separation of the subset with CIS. Recent prospective phase 2 and 3 studies have improved the evidence base. Conclusions We are beginning to understand that CIS has a spectrum of biologic potential. Bacillus Calmette-Guérin immunotherapy appears superior to other intravesical agents and may alter the natural history of CIS. New imaging modalities, agents, and treatment strategies have emerged in recent years with the aim of better identification of CIS, more bladder-preserving treatments, and prevention of surgical overtreatment. Patient summary Improvements in imaging techniques combined with new bladder-preserving treatments will continue to have an impact on the outcomes of bladder carcinoma in situ.

KW - Bacillus Calmette-Guérin

KW - Bladder

KW - Fluorescent cystoscopy

KW - Gemcitabine

KW - Hyperthermia

KW - Interferon-α

KW - Intravesical immunotherapy

KW - Narrow-band cystoscopy

KW - Photodynamic diagnosis

KW - Urothelial carcinoma in situ

KW - Valrubicin

UR - http://www.scopus.com/inward/record.url?scp=84964238197&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964238197&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2014.10.040

DO - 10.1016/j.eururo.2014.10.040

M3 - Article

C2 - 25466937

AN - SCOPUS:84964238197

VL - 67

SP - 876

EP - 888

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 5

ER -